Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)
India · Delayed Price · Currency is INR 424.80
+4.30 (1.02%)
At close: Jan 23, 2026
NSE:AKUMS Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 3,171 | 3,382 | -40.35 | 948.55 | -2,525 | 1,227 |
Depreciation & Amortization | 1,568 | 1,509 | 1,235 | 1,112 | 923.9 | 681.72 |
Other Amortization | 25.16 | 25.16 | 21.35 | 16.34 | 22.89 | 16.69 |
Loss (Gain) From Sale of Assets | -13.42 | 1.12 | 11.78 | 1.75 | 20.66 | 4.04 |
Asset Writedown & Restructuring Costs | -38.62 | -38.27 | -1.38 | 675.14 | 119.22 | 100 |
Loss (Gain) From Sale of Investments | - | - | - | - | - | -0.77 |
Loss (Gain) on Equity Investments | - | - | - | 2.03 | -2.03 | -3.47 |
Provision & Write-off of Bad Debts | 353.69 | 294.11 | 134.01 | 43.14 | 188.62 | 139.94 |
Other Operating Activities | -907.72 | -855.91 | 3,123 | -689.05 | 5,086 | 552.09 |
Change in Accounts Receivable | 1,677 | 341.05 | -32.32 | 349.11 | -3,718 | 361.48 |
Change in Inventory | 111.74 | -505.71 | 837.29 | -73.47 | -2,926 | -315.41 |
Change in Accounts Payable | 110.33 | 1,192 | -291.96 | -183.69 | 2,505 | -819.04 |
Change in Other Net Operating Assets | 9,409 | -692.95 | -14.34 | -435.29 | 623 | -638.18 |
Operating Cash Flow | 15,466 | 4,652 | 4,983 | 1,766 | 318.54 | 1,306 |
Operating Cash Flow Growth | 205.76% | -6.64% | 182.09% | 454.50% | -75.61% | - |
Capital Expenditures | -2,340 | -2,723 | -3,114 | -3,288 | -2,576 | -828.1 |
Sale of Property, Plant & Equipment | 100.66 | 85.47 | 249.93 | 421.47 | 19.24 | 9.38 |
Cash Acquisitions | - | - | - | -16.2 | -110.02 | -605 |
Investment in Securities | -10,886 | -3,091 | -634.75 | -449.53 | 247.07 | 254.6 |
Other Investing Activities | 418.29 | 249.86 | 121.02 | 303.9 | 46.31 | 66.77 |
Investing Cash Flow | -12,707 | -5,478 | -3,304 | -3,047 | -2,348 | -1,094 |
Short-Term Debt Issued | - | - | - | 485.79 | 2,524 | - |
Long-Term Debt Issued | - | - | 102.94 | 1,402 | 200.19 | 11.61 |
Total Debt Issued | -158.34 | - | 102.94 | 1,887 | 2,724 | 11.61 |
Short-Term Debt Repaid | - | -3,540 | -236.3 | - | - | -396.55 |
Long-Term Debt Repaid | - | -1,760 | -442.72 | -237.56 | -274.92 | -479.5 |
Total Debt Repaid | -4,951 | -5,301 | -679.02 | -237.56 | -274.92 | -876.05 |
Net Debt Issued (Repaid) | -5,110 | -5,301 | -576.08 | 1,650 | 2,450 | -864.44 |
Issuance of Common Stock | - | 6,374 | - | - | - | - |
Other Financing Activities | -178.61 | -345.08 | -504.13 | -404.43 | -89.1 | -50.18 |
Financing Cash Flow | -5,288 | 727.88 | -1,080 | 1,245 | 2,360 | -914.62 |
Miscellaneous Cash Flow Adjustments | - | - | -3.81 | - | - | 5.11 |
Net Cash Flow | -2,529 | -98.59 | 594.42 | -35.31 | 330.72 | -697.22 |
Free Cash Flow | 13,126 | 1,929 | 1,869 | -1,522 | -2,257 | 478.04 |
Free Cash Flow Growth | 619.43% | 3.23% | - | - | - | - |
Free Cash Flow Margin | 31.93% | 4.68% | 4.47% | -4.16% | -6.14% | 1.75% |
Free Cash Flow Per Share | 85.74 | 12.89 | 13.06 | -10.64 | -15.78 | 3.34 |
Cash Interest Paid | 178.61 | 345.08 | 504.13 | 404.43 | 89.1 | 50.18 |
Cash Income Tax Paid | 798.6 | 812.35 | 624.2 | 970.63 | 548.18 | 455.54 |
Levered Free Cash Flow | 2,651 | 1,082 | 794.71 | -1,950 | -2,550 | - |
Unlevered Free Cash Flow | 2,975 | 1,272 | 1,109 | -1,662 | -2,447 | - |
Change in Working Capital | 11,308 | 334.69 | 498.67 | -343.34 | -3,516 | -1,411 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.